These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26130070)

  • 21. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influences of teriparatide administration on marrow fat content in postmenopausal osteopenic women using MR spectroscopy.
    Yang Y; Luo X; Xie X; Yan F; Chen G; Zhao W; Jiang Z; Fang C; Shen J
    Climacteric; 2016 Jun; 19(3):285-91. PubMed ID: 26744910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
    Eastell R; Lang T; Boonen S; Cummings S; Delmas PD; Cauley JA; Horowitz Z; Kerzberg E; Bianchi G; Kendler D; Leung P; Man Z; Mesenbrink P; Eriksen EF; Black DM;
    Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic Resonance Spectroscopy for Evaluating the Effect of Pulsed Electromagnetic Fields on Marrow Adiposity in Postmenopausal Women With Osteopenia.
    Li S; Jiang H; Wang B; Gu M; Bi X; Yin Y; Wang Y
    J Comput Assist Tomogr; 2018; 42(5):792-797. PubMed ID: 29901507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study.
    Popp AW; Guler S; Lamy O; Senn C; Buffat H; Perrelet R; Hans D; Lippuner K
    J Bone Miner Res; 2013 Mar; 28(3):449-54. PubMed ID: 23018784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.
    Gamsjaeger S; Buchinger B; Zwettler E; Recker R; Black D; Gasser JA; Eriksen EF; Klaushofer K; Paschalis EP
    J Bone Miner Res; 2011 Jan; 26(1):12-8. PubMed ID: 20645415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
    J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G; Kriegman A; Gonçalves J; Kianifard F; Warren M; Simon JA
    Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.
    Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao DS; Miller PD; Woodson GC; Lindsay R; Binkley N; Wan X; Ruff VA; Janos B; Taylor KA
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2799-808. PubMed ID: 22701017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Yigu® versus Aclasta® in Chinese postmenopausal women with osteoporosis: a multicenter prospective study.
    Li M; Cheng Q; Huo YN; Chao AJ; He L; Xue QY; Xu J; Yan SG; Jin H; Zhang ZL; Lin JH; Jin XL; Xu YJ; Liu F; Xia WB
    Arch Osteoporos; 2022 Jan; 17(1):14. PubMed ID: 35020038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.
    McClung M; Miller P; Recknor C; Mesenbrink P; Bucci-Rechtweg C; Benhamou CL
    Obstet Gynecol; 2009 Nov; 114(5):999-1007. PubMed ID: 20168099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion.
    Chen F; Dai Z; Kang Y; Lv G; Keller ET; Jiang Y
    Osteoporos Int; 2016 Apr; 27(4):1469-1476. PubMed ID: 26556733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
    Boonen S; Orwoll E; Magaziner J; Colón-Emeric CS; Adachi JD; Bucci-Rechtweg C; Haentjens P; Kaufman JM; Rizzoli R; Vanderschueren D; Claessens F; Sermon A; Witvrouw R; Milisen K; Su G; Lyles KW;
    J Am Geriatr Soc; 2011 Nov; 59(11):2084-90. PubMed ID: 22091563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat.
    Gasser JA; Ingold P; Venturiere A; Shen V; Green JR
    J Bone Miner Res; 2008 Apr; 23(4):544-51. PubMed ID: 18072878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
    Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
    Dieckmeyer M; Ruschke S; Rohrmeier A; Syväri J; Einspieler I; Seifert-Klauss V; Schmidmayr M; Metz S; Kirschke JS; Rummeny EJ; Zimmer C; Karampinos DC; Baum T
    BMC Musculoskelet Disord; 2019 Nov; 20(1):515. PubMed ID: 31694630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.